Skip to content

Study on Liposomal Bupivacaine Applied in Nerve Block for Postoperative Analgesia of Knee Arthroplasty

Study on Liposomal Bupivacaine Applied in Nerve Block for Postoperative Analgesia of Knee Arthroplasty

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116746
Enrollment
Unknown
Registered
2026-01-14
Start date
2025-03-10
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Degenerative Joint Disease

Interventions

Control group:After general anesthesia induction, ultrasound-guided injection of ropivacaine hydrochloride was performed for posterior joint capsule space block (0.25%, 20ml) combined with adductor mu
Experimental Group:After general anesthesia induction, a liposomal bupivacaine injection was performed under ultrasound guidance for posterior joint capsule space block (20ml) combined with adductor m

Sponsors

The Second People's Hospital of Hefei
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. ASA anesthesia classification: Grade I - III; 2. Age: 18 years old to 90 years old, gender not restricted; 3. BMI: 18 - 30 kg/m^2; 4. Scheduled for total knee replacement under general anesthesia; 5. Able to understand and voluntarily sign the informed consent form, and willing to comply with the requirements of the trial protocol.

Exclusion criteria

Exclusion criteria: 1.Patients with hypersensitivity or contraindications to bupivacaine liposomes or other anesthetic agents; 2.Those with severe cardiac, pulmonary, or renal insufficiency, multiple chronic conditions that make them intolerant to surgical anesthesia, or psychiatric disorders; 3.Individuals with alcohol abuse history, opioid allergy, or history of opioid drug abuse; 4.Patients with impaired language, cognitive, or comprehension abilities that prevent normal communication; 5.Pregnant or breastfeeding women; 6.Emergency surgery patients; 7.Other circumstances deemed unsuitable for enrollment by the investigator;

Design outcomes

Primary

MeasureTime frame
Epinephrine;Inflammatory factor IL-17;Resting and exercise pain scores at 72h postoperative (T9);

Secondary

MeasureTime frame
Hemodynamics;First postoperative time for salvage analgesia;Patient operation time, anesthesia time, awakening time;Total sufentanil and remifentanil during surgery;

Countries

China

Contacts

Public ContactJun Zhang

The Second People's Hospital of Hefei

zhangjundzl@163.com+86 551 6220 3666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026